首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
【24h】

Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.

机译:熊去氧胆酸对原发性胆汁性肝硬化患者肝生化指标的预后因素和长期影响。荷兰多中心PBC研究小组。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND/AIMS: Serum bilirubin is a prognostic factor in untreated primary biliary cirrhosis (PBC), but this has been less extensively documented for patients treated with UDCA. The aims of this study were to define the effects of UDCA on serum liver tests and to assess prognostic factors in patients on prolonged UDCA treatment. METHODS: Analysis of laboratory parameters obtained before and during treatment with UDCA of 203 PBC patients who were followed for a mean of 48 months. Univariate and multivariate analyses were performed to assess the prognostic value of pre-entry and follow-up variables with respect to treatment failure and survival. RESULTS: Actuarial 5-year incidences of treatment failure and transplantion-free survival were 27 and 79%, respectively. According to the univariate analysis the following variables were significantly associated with prognosis: pre-entry presence of cirrhosis and pre-treatment levels of serum bilirubin and albumin, bilirubin levels during follow-up, the occurrence of biochemical remission and normalisation of serum bilirubin. Multivariate analysis revealed that bilirubin during follow-up was the best predictor. Alkaline phosphatase, aspartate aminotransferase and IgM decreased significantly during the first 6 months of treatment and subsequently remained at this lower level. Serum bilirubin showed the same initial pattern, but a significant increase was observed after 4 years of treatment. CONCLUSIONS: Serum bilirubin in both UDCA-treated and untreated patients is the most powerful predictor of prognosis for PBC. The partial therapeutic efficacy of UDCA is illustrated by the finding that serum bilirubin, in contrast to alkaline phosphatase and the transaminases, appears to increase after 4 years of treatment.
机译:背景/目的:血清胆红素是未经治疗的原发性胆汁性肝硬化(PBC)的预后因素,但是对于用UDCA治疗的患者,这方面的文献报道较少。这项研究的目的是确定UDCA对血清肝测试的影响,并评估长期UDCA治疗的患者的预后因素。方法:分析203例PBC患者的UDCA治疗前后的实验室参数,平均随访48个月。进行单因素和多因素分析以评估入院前和随访变量对治疗失败和生存的预后价值。结果:5年精算失败率和无移植生存率分别为27%和79%。根据单因素分析,以下变量与预后显着相关:肝硬化进入前的存在和血清胆红素和白蛋白的治疗前水平,随访期间胆红素水平,生化缓解的发生以及血清胆红素正常化。多变量分析显示,随访期间胆红素是最佳预测指标。碱性磷酸酶,天冬氨酸转氨酶和IgM在治疗的前6个月中显着下降,随后保持在较低水平。血清胆红素显示出相同的初始模式,但治疗4年后观察到显着增加。结论:UDCA治疗和未治疗患者的血清胆红素是PBC预后的最有力预测指标。 UDCA的部分治疗功效通过发现发现:与碱性磷酸酶和转氨酶相比,血清胆红素在治疗4年后似乎增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号